A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma

NCT02644967 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Melanoma

Interventions

DRUG: IMO-2125
DRUG: Ipilimumab

Sponsor

Idera Pharmaceuticals, Inc.